Taiho Oncology, Inc.: FDA Approves Taiho's LYTGOBI (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

LYTGOBI (pronounced "light-GOH-bee") delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI

Related Keywords

Oakville ,Ontario ,Canada ,United States ,New Jersey ,Switzerland ,Horsham ,Saskatchewan ,Massachusetts ,Canadian ,American ,Kostenloser Wertpapierhandel ,Teruhiro Utsugi ,Lipika Goyal ,Judy Kay Moore ,Gastroenterol Hepatol ,Tim Whitten ,Taiho Pharmaceutical Co Ltd ,Hospital Cancer Center ,Drug Administration ,Janssen Pharmaceutical Companies ,Taiho Oncology Inc ,Prnewswire Taiho Oncology Inc ,Otsuka Holdings Co Ltd ,Incyte Corporation ,American Cancer Society ,Taiho Oncology ,Massachusetts General Hospital Cancer Center ,Taiho Pharmaceutical ,Senior Managing Director ,Pigment Epithelial Detachment ,Corneal Keratitis ,Soft Tissue Mineralization ,Prescribing Information ,Oncology Media Contact ,Rev Gastroenterol ,Taiho ,Ncology ,Pproves ,Ytgobi ,Futibatinib ,Tablets ,Reviously ,Reated ,Unresectable ,Ocally ,Dvanced ,Metastatic ,Intrahepatic ,Cholangiocarcinoma ,